Compare AbCellera Biologics Inc (ABCL) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Main Street Capital Corporation — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Main Street Capital Corporation trades at $51.24 (market cap $4.87B). The key difference: Main Street Capital Corporation is far larger — about 2.1× AbCellera Biologics Inc's market cap, and Main Street Capital Corporation pays a 8.36% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MAIN | |
|---|---|---|
Market Cap | $2.35B | $4.87B |
Sector | Health | Financials |
52-Week High | $8.12 | $67.54 |
52-Week Low | $2.78 | $49.63 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Main Street Capital (MAIN) trades at $52.41, up 0.87% on the day, with a bullish technical signal and strong support near $52. The company reported a net income margin of 81.08% for 2025, though revenue declined slightly to $592 million. Recent corporate actions include a credit facility amendment extending maturity to 2031 and consistent dividend payments, highlighting its income-focused appeal.
Outlook remains mixed; the stock offers a high yield and stable dividends, but earnings misses and a high RSI suggest near-term caution. Analyst consensus is a Hold with a $57.75 price target, indicating modest upside potential amid execution risks and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
